-
Bristol-Myers Stock May Have Exhausted Its Upside For Now
Monday, October 16, 2017 - 10:08am | 533Read More...Jefferies said in a note Monday that upside asymmetry for Bristol-Myers Squibb Co (NYSE: BMY) is exhausted at current levels, with shares having already discounted M&A spec and biopharma flows. This, according to the firm, leaves significant downside risk if current study CM-227 fails. CM-...
-
Jefferies Raises Pfizer PT, Says Company Has Multiple Ways To Win
Monday, March 23, 2015 - 9:36am | 180Read More...Jefferies on Monday issued a report on Pfizer Inc. (NYSE: PFE), raising its price target from $42 to $45. Jefferies rates Pfizer as a Buy. Analysts Jeffrey Holland, David Gu, Ian Hilliker and Sissi Qiong Hai wrote, "We expect Pfizer shares to significantly appreciate over the next 1-2 years based...
